The evaluation of Cannabidiol’s effect on the immunotherapy of Burkitt lymphoma.
Biochem Biophys Res Commun. 2019 Oct 03;:
Authors: Togano T, Kim N, Kim N, Park GS, Park AK, Bennet M, Park J
AIM: AF1q has a precise oncogenic function. The purpose of this study is to investigate whether CBD has an effect on the AF1q/ICAM-1 regulatory axis in Burkitt’s lymphoma (BL), and thus has potential to enhance immunotherapy and reduce side effects.
METHODS: We established BL cell lines with altered AF1q expression using lentivirus. After confirmation of gene expression by RT-PCR, cells were treated with CBD followed by co-culture of killing assay.
RESULTS: AF1q increased oncogenic growth and colony formation, and induced resistance against cell-mediated cytotoxic chemotherapy through attenuation of ICAM-1 expression in BL. CBD was able to reverse the acquired resistance mediated by AF1q/ICAM-1 regulatory axis.
CONCLUSION: CBD holds potential to enhance the efficacy of immunotherapy for BL with hyperactive AF1q/ICAM-1 regulatory axis, and warrants further study.
PMID: 31587870 [PubMed – as supplied by publisher]